OncoMatch/Clinical Trials/NCT07225946
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Is NCT07225946 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including Pasritamig and Docetaxel for prostatic neoplasms, castration-resistant.
Treatment: Pasritamig · Docetaxel · Prednisone/Prednisolone — The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Prostate Cancer
Biomarker criteria
Excluded: BRCA1 mutation
Excluded: BRCA2 mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: androgen receptor pathway inhibitor — any stage of disease
Have progressed by PSA or CT/MRI or 99m^Tc bone scan on at least 1 novel androgen receptor pathway inhibition (ARPI) but no more than 2 different ARPI for any stage of disease. Must have discontinued ARPI before randomization into the study
Cannot have received: cytotoxic chemotherapy for prostate cancer
Received cytotoxic chemotherapy for prostate cancer in any setting
Cannot have received: KLK2-directed therapy
Received prior treatment with human kallikrein 2 (KLK-2) directed therapies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Providence Saint John s Health Center · Santa Monica, California
- Rocky Mountain Cancer Centers · Aurora, Colorado
- Vail Health Shaw Cancer Center · Edwards, Colorado
- Grand Valley Oncology · Grand Junction, Colorado
- Colorado Clinical Research · Lakewood, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07225946 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cytotoxic chemotherapy for prostate cancer, KLK2-directed therapy disqualifies patients from enrollment.
Are patients with BRCA1 alterations eligible?
No. BRCA1 mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages